Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma

Blood

Volumn 95, Issue 2, 2000, Pages 610-618

  Tinhofer, Inge ^a   Marschitz, Ingrid ^a   Henn, Traudi ^a   Egle, Alexander ^a   Greil, Richard ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CELL STIMULATION; CELL SURVIVAL; HUMAN; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034651023     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.610     Document Type: Article

References (51)

1. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interteukin-6. Blood. 1989:73:517-544.
2. Merico F, Bergui L, Gregoretti MG, et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol. 1993:92:27-31.
3. Cozzolino F, Torcia M, Aldinucci D, et al. Production of interleukin-1 by bone marrow myeloma cells. Blood. 1989:74:380-387.
4. Portier M, Zhang XG, Ursule E. et al. Cytokine gene expression in human multiple myeloma. Br J Haematol. 1993:85:514-520.
5. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988:332:83-89.
6. Garrett IR, Durie BG, Nedwin GE, et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med. 1987;317:526-532.
7. Nakamura M, Merchav S, Carter A, et al. Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol. 1989:143:3543-3547.
8. Zhang XG, Klein B, Bataille R. lnterleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood. 1989;74:1113.
9. Klein B, Zhang XG, Lu ZY, Bataille R. Interteukin-6 in human multiple myeloma. Blood. 1995; 85:863-872.
10. Westendorf JJ, Lammert JM, Jelinek DF. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood. 1995:85:3566-3576.
11. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interteukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995:162:248-255.
12. Hardin J, MacLeod S, Grigorieva I. et al. Interteukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994:84:3063-3070.
13. Chauhan D, Kharbanda S, Ogata A, et al. lnterleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227-234.
14. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interteukin-2 receptor. Science. 1994:264:965-968.
15. Carson WE, Fehniger TA, Haldar S, et al. A potential role for interteukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997:99:937-943.
16. Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol. 1995;154:483-490.
17. Bulfone Paus S, Ungureanu D, Pohl T, et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med. 1997:3:1124-1128.
18. Girt JG, Ahdieh M, Eisenman J, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13: 2822-2830.
19. GiriJG, KumakiS, Ahdieh M, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 1995:14:3654-3663.
20. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hématologie malignancy. Blood. 1997:90:2863-2892.
21. Tsudo M, Kitamura F, Miyasaka M. Characteriza-lion of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies. Proc Natl Acad Sei U S A. 1989;86:1982-1986.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
23. Yamada Y. Sugawara K, Hata T, et al. Interteukin-15 (IL-15) can replace the IL-2 signal in IL-2dependent adult T-cell leukemia (ATL) ceil lines: expression of IU-15 receptor alpha on ATL cells. Blood. 1998:91:4265-4272.
24. Bargou RC, Daniel PT, Mapara MY, et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer. 1995:60:854-859.
25. Villunger A, Egle A, Marschitz I, et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma ceils: a potential mechanism of tumor-induced suppression of immune surveillance. Blood. 1997:90:12-20.
26. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. AnnexinV for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415-1420.
27. Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondria! functionality during apoptosis. FEES Lett. 1997:411:77-82.
28. Anderson DM, Kumaki S, Ahdieh M, et al. Functional characterization of the human interteukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J Biol Chem. 1995; 270:29,862-29,869.
29. Kumaki S, Armitage R, Ahdieh M, Park L, Cosman D. lnterleukin-15 up-regulates interieukin-2 receptor alpha chain but down-regulates its own high-affinity binding sites on human T and B cells. Eur J Immunol. 1996:26:1235-1239.
30. Dobbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. lnterleukin-15 is an autocrine/ paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 1998:92:252-258.
31. Villunger A, Egle A, Kos M, HittmairA, Maly K. Greil R. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. Int J Cancer. 1996:65:498-505.
32. Levy Y, Tsapis A, Brouet JC. lnterleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest. 1991;88: 696-699.
33. Keller ET, Ershler WB. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J Immunol. 1995:154: 4091-4098.
34. Girard D, Paquet ME, Paquin R, Beaulieu AD. Differential effects of interieukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15. Blood. 1996;88: 3176-3184.
35. Egle A, Villunger A, Kos M, et al. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur J Immunol. 1996:26:3119-3126.
36. Egle A, Villunger A, Marschitz I, et al. Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between respon-
37. siveness to anti-Fas mAb and p53 functional status. Br J Haematol. 1997;97:418-428.
38. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood. 1995:85:757-764.
39. Meazza R, Verdiani S, Biassoni R. et al. Identification of a novel interteukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Oncogene. 1996:12:2187-2192.
40. Barzegar C, Meazza R, Pereno R, et al. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene. 1998:16:2503-2512.
41. Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity. 1996:4: 329-336.
42. Bamford RN, Battiata AP, Burton JD, Sharma H, Waldmann TA. Interteukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc Natl Acad Sei USA. 1996:93:2897-2902.
43. Mrozek E, Andersen P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 1996:87:2632-2640.
44. Oppenheimer-Marks N, Brezinschek RI, Mohamadzadeh M, Vita R, Lipsky PE. Interteukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells In vitro and in the SCID mouse-human rheumatoid arthritis model In vivo. J Clin Invest. 1998:101:1261-1272.
45. Doherty TM, Seder RA, Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol. 1996:156:735-741.
46. Demartis A, Bemassola F, Savino R, Melino G, Ciliberto G. Interteukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res. 1996:56:42134218.
47. Billadeau D, Jelinek DF, Shah N, LeBien TW, Van Ness B. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res. 1995:55:3640-3646.
48. Zhang XG. Bataille R, Jourdan M, et al. Granulocyte-macrophage colony-stimulating factor synergizes with interteukin-6 in supporting the proliferation of human myeloma cells [comments]. Blood. 1990:76:2599-2605.
49. Villunger A, Egle A, Kos M, et al. Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity. BrJ Haematol. 1998:102:1069-1080.
50. Xu FH, Sharma S, Gardner A, et al. lnterleukin-6induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood. 1998:92:241-251.
51. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999:10:105-115.